Alextthymia in male cannabis users: The role of comorbid depressive disorders

Depression Pub Date : 1995-01-01 DOI:10.1002/depr.3050030504
Gianfranco Spalletta M.D., Alfonso Troisi M.D., Augusto Pasini M.D.
{"title":"Alextthymia in male cannabis users: The role of comorbid depressive disorders","authors":"Gianfranco Spalletta M.D.,&nbsp;Alfonso Troisi M.D.,&nbsp;Augusto Pasini M.D.","doi":"10.1002/depr.3050030504","DOIUrl":null,"url":null,"abstract":"<p>Whereas there is strong evidence for a high prevalence of alexithymia among patients with alcohol dependence and mixed substance abuse, no study has investigated the association between cannabis use and alexithymia. In this study, we assessed the prevalence of alexithymia, as measured by the 20-item revised Toronto Alexithymia Scale (TAS-20), in a group of newly abstinent cannabis abusers (N = 60) who abused cannabis exclusively. We found a large difference in the rate of alexithymia between cannabis abusers with and without comorbid DSM-III-R depressive disorders. Only 7% of nondepressed cannabis-abusing subjects were alexithymic. In contrast, 57% of cannabis abusers with comorbid major depression, dysthymia, or adjustment disorder with depressed mood were alexithymic. The prevalence rate of alexithymia among the cannabis abusers with comorbid depressive disorders was similar to that (50%) found in a control group of pure depressives, even though the TAS-20 F1 subscale discriminated between the two groups (depressed cannabis abusers had more difficulty identifying their feelings than pure depressives). These results suggest that a syndromal diagnosis of comorbid depression may be a major confounding variable in the assessment of alexithymia (as measured by the TAS total score) among subjects with cannabis abuse and dependence. Depression 3:246–249 (1995/1996). © 1996 Wiley-Liss, Inc.</p>","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 5","pages":"246-249"},"PeriodicalIF":0.0000,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030504","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Depression","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/depr.3050030504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Whereas there is strong evidence for a high prevalence of alexithymia among patients with alcohol dependence and mixed substance abuse, no study has investigated the association between cannabis use and alexithymia. In this study, we assessed the prevalence of alexithymia, as measured by the 20-item revised Toronto Alexithymia Scale (TAS-20), in a group of newly abstinent cannabis abusers (N = 60) who abused cannabis exclusively. We found a large difference in the rate of alexithymia between cannabis abusers with and without comorbid DSM-III-R depressive disorders. Only 7% of nondepressed cannabis-abusing subjects were alexithymic. In contrast, 57% of cannabis abusers with comorbid major depression, dysthymia, or adjustment disorder with depressed mood were alexithymic. The prevalence rate of alexithymia among the cannabis abusers with comorbid depressive disorders was similar to that (50%) found in a control group of pure depressives, even though the TAS-20 F1 subscale discriminated between the two groups (depressed cannabis abusers had more difficulty identifying their feelings than pure depressives). These results suggest that a syndromal diagnosis of comorbid depression may be a major confounding variable in the assessment of alexithymia (as measured by the TAS total score) among subjects with cannabis abuse and dependence. Depression 3:246–249 (1995/1996). © 1996 Wiley-Liss, Inc.

男性大麻使用者的嗅觉障碍:共病抑郁症的作用
虽然有强有力的证据表明,酒精依赖和混合药物滥用患者中述情障碍的患病率很高,但没有研究调查大麻使用与述情障碍之间的关系。在这项研究中,我们评估了一组新近戒断大麻滥用者(N = 60)述情障碍的患病率,通过20项修订的多伦多述情障碍量表(TAS-20)进行测量。我们发现大麻滥用者与未合并DSM-III-R抑郁障碍的述情障碍发生率有很大差异。只有7%的非抑郁大麻滥用者有述情障碍。相比之下,57%的大麻滥用者同时患有重度抑郁症、心境恶劣或调节障碍,并伴有抑郁情绪。尽管TAS-20 F1分量表在两组之间存在差异(抑郁的大麻滥用者比纯粹的抑郁症患者更难识别自己的感受),但合并抑郁症的大麻滥用者述情障碍的患病率与纯抑郁症控制组相似(50%)。这些结果表明,共病性抑郁症的综合征诊断可能是评估大麻滥用和依赖受试者述情障碍(以TAS总分衡量)的主要混杂变量。大萧条:246 - 249(1995/1996)。©1996 Wiley-Liss, Inc
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信